<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="P491 Prospective multi-modal MRI study to examine the effect of" exact="natalizumab" post="on tissue injury in the brain and spinal cord"/>
 <result pre="is not well understood. Objectives: To determine the effect of" exact="natalizumab" post="(NTZ) on brain tissue injury and cervical cord volume"/>
 <result pre="and TCI assessed by TMS-evoked potentials in MS subjects on" exact="glatiramer acetate." post="This relationship may guide the use of MWF for"/>
 <result pre="MRI markers to assess protection and repair in response to" exact="fingolimod" post="C Berrios-Otero 1, L Fleysher 2, J Zhang 1,"/>
 <result pre="examined 210 CIS patients treated with 30 µg of intramuscular" exact="interferon beta-1a" post="once a week. MRI and clinical assessments were performed"/>
 <result pre="pseudoatrophy effect. We have recently studied brain volume changes on" exact="natalizumab" post="treatment assessing the effect of baseline gadolinium-enhancing (Gd+) lesions"/>
 <result pre="RMS who had been treated with Interferon beta (IFN) or" exact="glatiramer acetate" post="(GA) for 12 months or longer. Types, indications, and"/>
 <result pre="and laquinimod were classified as first-line DMD and natalizumab, fingolimod," exact="daclizumab" post="and alemtuzumab classified as second-line ones. To compare effect"/>
 <result pre="were classified as first-line DMD and natalizumab, fingolimod, daclizumab and" exact="alemtuzumab" post="classified as second-line ones. To compare effect of DMD,"/>
 <result pre="A prospective, case-control, longitudinal MRI study of the effect of" exact="glatiramer acetate" post="on iron deposition in RRMS R Zivadinov 1, C"/>
 <result pre="multiple sclerosis (MS) patients. Objectives: To explore whether treatment with" exact="glatiramer acetate" post="(GA) may alter iron deposition and atrophy accumulation in"/>
 <result pre="to substantial therapeutic promise for autoimmune disorders. P561 Role of" exact="melatonin" post="in MS pathogenesis MF Farez 1, S Mendez Huergo"/>
 <result pre="were found during fall and winter, with inverse correlation to" exact="melatonin" post="levels assayed. We aim to determine whether melatonin exerts"/>
 <result pre="correlation to melatonin levels assayed. We aim to determine whether" exact="melatonin" post="exerts a protective effect on MS, and if so,"/>
 <result pre="of this effect might be. Objectives: Characterize the role of" exact="melatonin" post="in MS pathogenesis. Methods: One hundred and nineteen patients"/>
 <result pre="samples were taken every three months during one year and" exact="melatonin" post="metabolite levels determined in urine by ELISA. EAE was"/>
 <result pre="Results: We found an inverse correlation between exacerbation rates and" exact="melatonin" post="levels for each season (Spearman’s rho -0.73, P=0.006). Higher"/>
 <result pre="melatonin levels for each season (Spearman’s rho -0.73, P=0.006). Higher" exact="melatonin" post="levels observed during fall and winter correlated with lower"/>
 <result pre="winter correlated with lower disease activity. We then tested whether" exact="melatonin" post="had an effect on EAE. Decreased disease incidence (65%"/>
 <result pre="1.89±0.8 vs 2.65±1.4, P=0.049) were observed in mice treated with" exact="melatonin" post="compared to vehicle-treated mice. This effect was related to"/>
 <result pre="CD4 +Foxp3 + T reg (4.45±0.4 vs 6.55±0.4, P=0.009). Finally," exact="melatonin" post="affected in vitro differentiation of naïve CD4 + T"/>
 <result pre="as well as patients on four common immunomodulatory treatments (interferon-beta," exact="glatiramer acetate," post="natalizumab, FTY720) applied in a routine tertiary outpatient clinic."/>
 <result pre="in patients with progressive MS; to investigate the effect of" exact="natalizumab" post="on these cell subsets; and to examine if these"/>
 <result pre="healthy controls (HC) (n=31). Nine SPMS and PPMS patients received" exact="natalizumab" post="for 60 weeks. Patients were scored on expanded disability"/>
 <result pre="in systemic inflammation of progressive MS patients and decreases during" exact="natalizumab" post="treatment. Furthermore, we hypothesize that their negative correlation with"/>
 <result pre="T cell behavior is significantly altered in MS patients undergoing" exact="methylprednisolone" post="pulse therapy (Acta Neuropathologica 127, 713-29), we are currently"/>
 <result pre="between pDCs and mechanisms of MS. P574 Neuroprotective effects of" exact="calcitriol" post="in autoimmune optic neuritis K-W Sühs 1, K Pars"/>
 <result pre="were randomly assigned to be treated with either vehicle or" exact="calcitriol" post="1 mg/kg i.p.. On day 8 of clinical manifest"/>
 <result pre="in clinical disease severity, demyelination (LFB: vehicle 72.2% ± 9.582%;" exact="calcitriol" post="79.72% ± 7.334%; p&amp;lt; 0.5421), acute axonal damage (β-APP:"/>
 <result pre="p&amp;lt; 0.5421), acute axonal damage (β-APP: vehicle 5.40 ± 1.516;" exact="calcitriol" post="3.939 ± 2.927 positive axons per mm 2; p&amp;lt;"/>
 <result pre="p&amp;lt; 0.712), chronic axonal damage (Bielschowsky: vehicle 9.517% ± 1.472%;" exact="calcitriol" post="9.204% ± 1.625%; p&amp;lt; 0.8949), and infiltrating cells (HE:"/>
 <result pre="p&amp;lt; 0.8949), and infiltrating cells (HE: vehicle 2.391 ± 0.2154;" exact="calcitriol" post="2.667 ± 0.2462 cells per mm 2; p&amp;lt; 0.4342)"/>
 <result pre="RGCs in vehicle- versus calcitiriol-treated animals. (vehicle 651.6 ± 56.21;" exact="calcitriol" post="926 ± 87.72 cells per mm2; p&amp;lt; 0.0101). Conclusions:"/>
 <result pre="926 ± 87.72 cells per mm2; p&amp;lt; 0.0101). Conclusions: Despite" exact="calcitriol" post="did not show any anti-inflammatory effects, we found a"/>
 <result pre="metabolism, also exert immunomodulatory activity. Objectives: To evaluate effects of" exact="metformin" post="and thioazolinediones on immune regulation in obese MS patients"/>
 <result pre="who also developed metabolic syndrome, were studied. Fourteen patients received" exact="metformin" post="and 6 patients were given pioglitazone as treatment. Patients"/>
 <result pre="studied. Fourteen patients received metformin and 6 patients were given" exact="pioglitazone" post="as treatment. Patients underwent complete neurological examination every 3"/>
 <result pre="regulatory T cells were evaluated by flow cytometry. Results: After" exact="metformin" post="and pioglitazone treatment, MRIs showed significant decreased in number"/>
 <result pre="cells were evaluated by flow cytometry. Results: After metformin and" exact="pioglitazone" post="treatment, MRIs showed significant decreased in number of new"/>
 <result pre="CD25+ FoxP3+ regulatory T cells (p=0.01 to p&amp;lt; 0.0001). Meanwhile," exact="pioglitazone" post="induced significant activation of PPAR-g, and robust fall in"/>
 <result pre="role of T regulatory cells in the therapeutic effect of" exact="glatiramer acetate" post="in experimental autoimmune encephalomyelitis R Aharoni 1, T Feferman"/>
 <result pre="fashion, in the therapeutic effect of GA. P587 Impact of" exact="minocycline" post="and established MS medications on EMMPRIN, a new factor"/>
 <result pre="on cell viability and proliferation. At concentrations (5-10 µg/mL) of" exact="minocycline" post="that are encountered in MS subjects on this medication,"/>
 <result pre="established MS immunomodulators, interferon-beta (10-1000 U/mL) reduced EMMPRIN expression, while" exact="fingolimod" post="(100-300 ng/mL) was without effect. Conclusions: An emerging (minocycline)"/>
 <result pre="and 43 RRMS patients treated with DMD (interferon-beta (IFNb; n=16);" exact="glatiramer acetate" post="(GA; n=8); fingolimod (F; n=9); and natalizumab (NTZ; n=10))."/>
 <result pre="treated with DMD (interferon-beta (IFNb; n=16); glatiramer acetate (GA; n=8);" exact="fingolimod" post="(F; n=9); and natalizumab (NTZ; n=10)). Results: No statistically"/>
 <result pre="(IFNb; n=16); glatiramer acetate (GA; n=8); fingolimod (F; n=9); and" exact="natalizumab" post="(NTZ; n=10)). Results: No statistically significant differences were observed"/>
 <result pre="both in vitro and in vivo and included alterations in" exact="tryptophan" post="metabolism and small molecule precursors involved in the synthesis"/>
 <result pre="the importance of this pathway, we supplemented cuprizone-treated cells with" exact="nicotinamide" post="and found that the addition of this compound could"/>
 <result pre="incidence and disease severity. P599 Suppression of IL-10 production by" exact="calcitriol" post="in patients with multiple sclerosis M Niino 1, T"/>
 <result pre="Objectives: The aim of this study was to investigate whether" exact="calcitriol" post="(1,25-dihydroxyvitamin D) differentially modulates cytokine production by peripheral blood"/>
 <result pre="( p = 0.0192), suggesting a stronger suppressive effect of" exact="calcitriol" post="on this anti-inflammatory cytokine in MS. Conversely, LPS-evoked IL-12/IL-23(p40)"/>
 <result pre="cytokine in MS. PHA-stimulated IL-10 production in the presence of" exact="calcitriol" post="was negatively correlated with the Expanded Disability Status Scale"/>
 <result pre="cell-based, and in vivo assays across relevant biologic activities of" exact="glatiramer acetate." post="P601 The ubiquitin-like modifier HLA-F adjacent transcript is upregulated"/>
 <result pre="was surprising and should stimulate further research. P603 Natalizumab and" exact="fingolimod" post="differentially impact the alpha-4/beta-1 and alpha-L/beta-2 expression-related subset diversity"/>
 <result pre="immune cells into the central nervous system. Natalizumab (NZB) and" exact="fingolimod" post="(FTY) are two efficacious treatment options in relapsing-remitting multiple"/>
 <result pre="Background: One approved therapy of patients with relapsing-remitting MS is" exact="glatiramer acetate" post="(GA). It is well established that GA among other"/>
 <result pre="identified in relapsing-remitting (RRMS) patients or in response to intravenous" exact="methylprednisolone" post="(IVMP), the standard treatment for MS relapses. The SMAD"/>
 <result pre="Methods: MS patients from the Partners MS Center [untreated (n=22)," exact="glatiramer acetate" post="treated (n=13), and IFN-β treated (n=18)] and healthy controls"/>
 <result pre="MS irrespective of whether they were treated with IFN-β or" exact="glatiramer acetate." post="Immune cell analysis showed that the antigen presenting cells"/>
 <result pre="significant genus-level differences in the microbiomes of patients treated with" exact="glatiramer acetate" post="compared to untreated subjects. Significant enrichment of members of"/>
 <result pre="75 samples (53% positive, 47% negative). Treatment with plasmapheresis and" exact="methylprednisolone" post="in acute stage. Immunosuppressive therapy: 98% Azathioprine and 2%"/>
 <result pre="in patient with neuromyelitis optica after treatment with anti-IL-6R antibody" exact="tocilizumab" post="T Matsuoka 1, A Chiba 2, T Aranami 1,"/>
 <result pre="an exploratory study to evaluate the safety and efficacy of" exact="tocilizumab" post="(TCZ), a humanized anti-IL-6R monoclonal antibody, in NMO, and"/>
 <result pre="therapy. Objectives: To compare the efficacy of high dose intravenous" exact="methylprednisolone" post="(IVMP) versus high dose IVMP + PLEX in the"/>
 <result pre="and from medical records. All patients were under use of" exact="prednisone" post="in combination with other immunosuppressive drug (azathioprine or mycophenolato"/>
 <result pre="compared to the ‘on’ individual treatment rates (± prednisolone) were:" exact="azathioprine" post="(n=66, 63 1 st line) 0.93:0.21, methotrexate (n=16, 6"/>
 <result pre="(± prednisolone) were: azathioprine (n=66, 63 1 st line) 0.93:0.21," exact="methotrexate" post="(n=16, 6 1 st line) 1.9:0.44, mycophenolate mofetil (n=17,"/>
 <result pre="line) 1.9:0.44, mycophenolate mofetil (n=17, 4 1 st line) 0.76:0.50," exact="rituximab" post="(n=10, 1 1 st line) 0.76:0.46. Immunosuppressive treatment appeared"/>
 <result pre="12 (42.85%) occured during exposure to infliximab, 10 (35.7%) during" exact="adalimumab" post="and 8 (28.57%) during etanercept, mainly required because of"/>
 <result pre="treatment was respectively 8.5, 13.5 and 9 months for infliximab," exact="adalimumab" post="and etanercept. Clinical characteristics of ON were not specific,"/>
 <result pre="science experiments suggest that acid sensing ion channel blockade by" exact="amiloride" post="is neuro- and myelo-protective in models of MS. The"/>
 <result pre="2013. The aim is to assess the neuroprotective efficacy of" exact="amiloride" post="in acute optic neuritis. Objectives: To evaluate structural and"/>
 <result pre="sulfhydryl groups of proteins were evaluated by a spectrophotometric assay;" exact="nitric oxide" post="metabolites (NOx) levels were assessed by nitrite and nitrate"/>
 <result pre="(SV), and pulsatility index (PI). Blood samples were drawn for" exact="nitric oxide," post="von Willebrand factor (vWF), ICAM-1 and VCAM-1 ELISA determination."/>
 <result pre="pathway white matter was verified in individual cases by including" exact="lidocaine" post="(a reversible sodium channel blocker) in the injection solution"/>
 <result pre="P706 Transient and steady-state visual evoked potentials during treatment with" exact="fampridine" post="A Romani 1, N Visigalli 2, E Colombo 2,"/>
 <result pre="conduction blocks. Objectives: to assess if VEPs are influenced by" exact="fampridine" post="treatment; to compare the effects of treatment on transient"/>
 <result pre="The procedures were performed basally and after 15 days on" exact="fampridine" post="10 mg twice a day. Patients were classified as"/>
 <result pre="response. Conclusions: VEPs are able to document the effect of" exact="fampridine" post="in MS patients. VEP-tr seem to be less sensitive"/>
 <result pre="Objectives: We assessed the effect of the NMDA receptor blockers" exact="memantine" post="and MK-801, in a rat model of optic neuritis,"/>
 <result pre="immunization. Methods: Female BN rats were treatment with either vehicle," exact="memantine" post="hydrochloride 20 mg/kg (M20) or 60 mg/kg (M60), or"/>
 <result pre="oligodendrocytes was performed. Results: Disease severity was significantly lower in" exact="memantine" post="treated groups. By immunohistochemistry demyelination (LFB: vehicle, 84.7%; M20"/>
 <result pre="rapidly in both cell types. However preincubation with 12 µM" exact="memantine" post="significantly reduced the calcium response only in RGCs, confirmed"/>
 <result pre="for therapeutic neuroprotective strategies. P710 NDC-1308, a gain of function" exact="estradiol" post="analog for inducing remyelination in multiple sclerosis patients SH"/>
 <result pre="brain lesions and clinical relapses. In Phase 3 clinical trials," exact="fingolimod" post="showed significant reductions in both focal lesions and rate"/>
 <result pre="an active comparator. Objectives: To investigate if the effects of" exact="fingolimod" post="0.5 mg on BV loss are mediated through its"/>
 <result pre="are mediated through its effects on focal damage or if" exact="fingolimod" post="also acts independently in reducing diffuse damage. Methods: In"/>
 <result pre="to quantify whether the extent of treatment effect seen with" exact="fingolimod" post="vs. pbo in the overall population (unadjusted model), would"/>
 <result pre="difference in PBVC of -0.49% (&amp;lt; 0.001) in favor of" exact="fingolimod" post="vs pbo over 24 M was observed and was"/>
 <result pre="regression model suggests that 57% (-0.28%/-0.49%) of the effects of" exact="fingolimod" post="on PBVC are independent of its effects on focal"/>
 <result pre="of its effects on focal damage. Conclusions: The effect of" exact="fingolimod" post="on diffuse damage is partly independent of its treatment"/>
 <result pre="of its treatment effect on focal damage. This suggests that" exact="fingolimod" post="has an effect on both inflammatory and neurodegenerative components"/>
 <result pre="to 0.2% (w/w) cuprizone and supplemented with either low dose" exact="cholecalciferol" post="(&amp;lt; 50 IU/kg or 500 IU/kg) or high dose"/>
 <result pre="cholecalciferol (&amp;lt; 50 IU/kg or 500 IU/kg) or high dose" exact="cholecalciferol" post="(6200 IU/kg or 12500 IU/kg). The mice were euthanized"/>
 <result pre="cuprizone for five weeks, and then treated with either 0.2µg" exact="calcitriol" post="or placebo intraperitoneally twice weekly. Mice were sacrificed after"/>
 <result pre="cuprizone exposure, there was a significant effect of high dose" exact="cholecalciferol" post="on the extent of axonal loss, as measured by"/>
 <result pre="that randomized 1008 participants to combination therapy [interferon (IFN) and" exact="glatiramer acetate" post="(GA)] versus each agent alone plus placebo. The core"/>
 <result pre="3 new oral DMTs, FDA approved: fingolimod, dimethyl fumarate and" exact="teriflunomide" post="for at least one dose before 18 years of"/>
 <result pre="were identified across 7 participating sites. Ten patients were on" exact="fingolimod" post="and 18 on dimethyl fumarate. Twenty-three patients were previously"/>
 <result pre="previous DMTs before switching to oral therapies were as follows:" exact="glatiramer acetate" post="(n=2), interferon B-1a (IM n=6; SQ n=6), interferon B-1b"/>
 <result pre="(n=2), interferon B-1a (IM n=6; SQ n=6), interferon B-1b (n=3)," exact="natalizumab" post="(n=5); IVIG (n=1). The previous DMTs were discontinued due"/>
 <result pre="(n=2). Three patients discontinued (D/C) the oral DMTs; 1 D/C" exact="fingolimod" post="and switched to tecfidera due to efficacy concerns, 2"/>
 <result pre="This study examined 210 CIS patients treated with weekly intramuscular" exact="interferon beta-1a." post="All the CIS patients who entered the study showed"/>
 <result pre="multiple sclerosis (RRMS) treated with any interferon-beta (IFNβ) preparation or" exact="glatiramer acetate" post="(GA) as a first therapy. Methods: Data were extracted"/>
 <result pre="3b, randomized, double-blind, placebo-controlled study to evaluate the efficacy of" exact="natalizumab" post="on reducing disability in patients with SPMS. The primary"/>
 <result pre="1 1Biogen Idec, Cambridge, MA, United States Background: Prolonged-release (PR)" exact="fampridine" post="tablet (dalfampridine extended release tablets in the US) improves"/>
 <result pre="389 adult patients with MS initiating a treatment with intramuscular" exact="interferon beta-1a" post="were enrolled. Psychometric properties of the MSKQ, including quality"/>
 <result pre="same dose regimen in ENDORSE. Patients receiving PBO (DEFINE/CONFIRM) and" exact="glatiramer acetate" post="(GA) (CONFIRM) were randomized 1:1 to blinded treatment with"/>
 <result pre="patients, 1214 patients used injectable interferon and 491 patients injected" exact="glatiramer acetate." post="In the first study year, 411 patients relapsed at"/>
 <result pre="satisfaction and QoL data for patients with RR-MS treated with" exact="fingolimod" post="or other DMTs. Methods: Patients with RR-MS considering a"/>
 <result pre="respectively. 6h first dose monitoring (FDM) data were collected for" exact="fingolimod" post="treated patients. Results: 212 patients started treatment with fingolimod."/>
 <result pre="or adverse events during the FDM. 99.5% of patients continued" exact="fingolimod" post="treatment after the FDM. At FU (mean 8.3 ±"/>
 <result pre="8.3 ± 3.2 months after FDM), 96% of patients continued" exact="fingolimod" post="treatment. All domains of the TSQM-9 (effectiveness, convenience, global"/>
 <result pre="switch and in treatment-naïve patients, suggestive of high satisfaction with" exact="fingolimod" post="treatment in both types of patients. QoL (total MSIS-29"/>
 <result pre="Conclusions: In this real-world setting, efficacy, tolerability and safety of" exact="fingolimod" post="were in line with data reported in Phase 3"/>
 <result pre="with data reported in Phase 3 trials. Treatment satisfaction with" exact="fingolimod" post="was high in both treatment-naïve and switch patients, while"/>
 <result pre="a randomized, double-blind, placebo-controlled study, assessed the efficacy of subcutaneous" exact="peginterferon beta-1a" post="(PEG-IFN) 125 µg administered every 2 or 4 weeks"/>
 <result pre="sclerosis (RRMS). In the 2-year phase 3 CARE-MS II study," exact="alemtuzumab" post="demonstrated superior benefits in relapse rate, disability, and patient-reported"/>
 <result pre="in relapse rate, disability, and patient-reported outcomes (PROs) over subcutaneous" exact="interferon beta-1a" post="(SC IFNB-1a) in RRMS patients who relapsed on prior"/>
 <result pre="(NCT00548405), patients were randomized to receive 2 annual courses of" exact="alemtuzumab" post="12 mg (n=426) or SC IFNB-1a 44 µg 3"/>
 <result pre="new potential avenue for rehabilitation. P813 Understanding patient comprehension in" exact="natalizumab" post="administration/discontinuation and JC virus serology - a pilot study"/>
 <result pre="provided to patients with relapsing MS (RMS) who are prescribed" exact="interferon beta-1a" post="subcutaneously three times a week (IFN β-1a SC). Objectives:"/>
 <result pre="an effect on perinatal outcome. Objectives: To determine safety of" exact="glatiramer acetate" post="(GLAT) exposure during pregnancy of patients with multiple sclerosis"/>
 <result pre="small, further studies are needed to prove the safety of" exact="glatiramer acetate" post="exposure during pregnancy in MS. P839 Delayed-release dimethyl fumarate"/>
 <result pre="and for 3 of 4 pregnancies in subjects who received" exact="glatiramer acetate" post="(GA). Information is pending for 5 patients who received"/>
 <result pre="Japanese women, as previously reported. P842 Pregnancy outcomes in the" exact="alemtuzumab" post="MS clinical development program P McCombe 1, A Achiron"/>
 <result pre="of relapsing-remitting multiple sclerosis (RRMS), showed superior efficacy over subcutaneous" exact="interferon beta-1a" post="(SC IFNB-1a) and manageable safety in 3 randomized studies."/>
 <result pre="(NCT00530348) and CARE-MS II (NCT00548405) core studies, RRMS patients received" exact="alemtuzumab" post="intravenously 12 or 24 mg/day (only 12 mg in"/>
 <result pre="times weekly. Follow-up continued in an extension (NCT00930553) with as-needed" exact="alemtuzumab" post="re-treatment (first-time treatment for former SC IFNB-1a patients). Contraception"/>
 <result pre="did occur. Patients becoming pregnant could remain on study with" exact="alemtuzumab" post="suspended. Information on pregnancy outcomes and SAEs in fetuses/infants"/>
 <result pre="29 ongoing. Most pregnancies (133/139) occurred &amp;gt;4 months after last" exact="alemtuzumab" post="dose. Spontaneous abortion rate was age-related (overall: 17% of"/>
 <result pre="data. P843 Pregnancy outcomes and disease activity after exposure to" exact="natalizumab" post="in patients with multiple sclerosis E Portaccio 1, B"/>
 <result pre="multiple sclerosis (MS) patients. Objectives: To assess the impact of" exact="natalizumab" post="on pregnancy outcomes in an Italian cohort of MS"/>
 <result pre="in an Italian cohort of MS patients. Methods: We recruited" exact="natalizumab" post="exposed (NE) pregnancies in MS patients prospectively followed-up in"/>
 <result pre="in Italian MS Centres, in the period 2010-2013. Exposure to" exact="natalizumab" post="was defined as suspension of the drug &amp;lt; three"/>
 <result pre="show any major safety issues due to pregnancy exposure to" exact="natalizumab" post="in terms of spontaneous abortion and other outcomes. Detailed"/>
 <result pre="for female patients and partners of male patients in the" exact="teriflunomide" post="clinical development program B Kieseier 1, M Benamor 2,"/>
 <result pre="a potential risk of teratogenicity associated with teriflunomide. During the" exact="teriflunomide" post="clinical studies, pregnancy was therefore excluded before starting treatment,"/>
 <result pre="enrolled in the phase 2 and 3 studies in the" exact="teriflunomide" post="clinical development program. Methods: Patients received teriflunomide 14 mg"/>
 <result pre="studies in the teriflunomide clinical development program. Methods: Patients received" exact="teriflunomide" post="14 mg or 7 mg, interferon beta, or placebo."/>
 <result pre="of 83 pregnancies in female patients were reported in the" exact="teriflunomide" post="clinical trial program; of these, 70 occurred in women"/>
 <result pre="free of structural or functional abnormalities. Conclusions: Data from the" exact="teriflunomide" post="clinical development program have shown no evidence of human"/>
 <result pre="treated with leflunomide. Pregnancy outcomes among female patients who received" exact="teriflunomide" post="and partners of teriflunomide-treated male patients were consistent with"/>
 <result pre="patients were consistent with those in the non-MS population. Global" exact="teriflunomide" post="pregnancy registries are presently collecting prospective data from pregnancies"/>
 <result pre="patients showed significantly higher concentrations of prolactin, total and free" exact="testosterone" post="and a significantly lower serum concentration of 17-β-estradiol. MS"/>
 <result pre="MS varies by the type of progestin or amount of" exact="ethinyl estradiol" post="contained in combined oral contraceptives (COC). Methods: We conducted"/>
 <result pre="varies by the type of progestin or amount of ethinyl" exact="estradiol" post="contained in combined oral contraceptives (COC). Methods: We conducted"/>
 <result pre="than one type. The most common progestins in COCs were" exact="norethindrone" post="and levonorgestrel . Most COCs used contained between 0.03"/>
 <result pre="type. The most common progestins in COCs were norethindrone and" exact="levonorgestrel" post=". Most COCs used contained between 0.03 and 0.049mg"/>
 <result pre=". Most COCs used contained between 0.03 and 0.049mg of" exact="ethinyl estradiol." post="Ever having used any COC in the 10 years"/>
 <result pre="and ten community-referred, with PML occurring after 14-70 months of" exact="natalizumab" post="treatments. Two had prior immunosuppressants. Objectives: To present an"/>
 <result pre="The initial variably added plasma exchange, oral mefloquin, mirtazapine, and" exact="maraviroc" post="evolved as inessential. Anticonvulsants and unaggressive corticoids are administered"/>
 <result pre="with delayed diagnosis. Early and frequent MRIs and administration of" exact="filgrastim" post="likely contributed to favorable resolution of PML/IRIS in 8"/>
 <result pre="index &amp;gt;1.5, the risk of PML is about 1:125. Thus," exact="natalizumab" post="discontinuation is highly suggested in these patients and a"/>
 <result pre="MS patients, the risk and timing of disease reactivation after" exact="natalizumab" post="discontinuation. Methods: In the period March 2011-September 2013, natalizumab"/>
 <result pre="after natalizumab discontinuation. Methods: In the period March 2011-September 2013," exact="natalizumab" post="was stopped in 66 RRMS patients. Reasons for discontinuation"/>
 <result pre="case of relapse. Results: Between month 4 and 6 after" exact="natalizumab" post="break, clinical and/or neuroimaging evidence of disease reactivation was"/>
 <result pre="independently from the subsequent therapeutic options, a three month-washout after" exact="natalizumab" post="is hazardous since it exposes the patients to a"/>
 <result pre="safety outcomes in MS patients who either receive DMT (including" exact="fingolimod" post="according to approved label) or who are on no"/>
 <result pre="the longitudinal distribution of lymphocyte count and LFT abnormalities in" exact="fingolimod" post="treated patients. Methods: Data from the module was extracted"/>
 <result pre="and 7 NMSC on any other DMT. 575 patients on" exact="fingolimod" post="contributed 2300 lymphocyte counts and LFT’s. Of these, 21"/>
 <result pre="serum samples in four MS patients who developed PML during" exact="natalizumab" post="treatment in the MS Center Amsterdam, The Netherlands. Sampling"/>
 <result pre="MS Center Amsterdam, The Netherlands. Sampling took place from before" exact="natalizumab" post="initiation until the development of PML. Indexes were compared"/>
 <result pre="compared to those from all other MS patients treated with" exact="natalizumab" post="in the MS Center Amsterdam (n=140). Anti- JVC antibodies"/>
 <result pre="needs to be confirmed. P862 Varicella-zoster virus (VZV) experience in" exact="fingolimod" post="clinical studies and the post-marketing setting D Bischof 1,"/>
 <result pre="cells. In controlled clinical studies, the overall infection rate with" exact="fingolimod" post="0.5 mg was similar to that with placebo. In"/>
 <result pre="case of a varicella-zoster virus (VZV) infection was reported with" exact="fingolimod" post="0.5 mg. Objectives: To report the rate and severity"/>
 <result pre="To report the rate and severity of VZV infections with" exact="fingolimod" post="0.5 mg in clinical studies and in PMS. Methods:"/>
 <result pre="As of 28 Feb 2014, more than 91,500 patients received" exact="fingolimod" post="in clinical trials and the PMS with at least"/>
 <result pre="showed that the rates of VZV infections were 11 with" exact="fingolimod" post="0.5 mg vs. 6/1000 PY with placebo, and were"/>
 <result pre="cutaneous HZ constituted 95% of all cases (10.4/1000 PY with" exact="fingolimod" post="0.5 mg); no cases of disseminated HZ were reported"/>
 <result pre="reporting system database, the proportion of serious HZ infections on" exact="fingolimod" post="is comparable to other MS DMTs. Non-cutaneous manifestations were"/>
 <result pre="been reported to date. Conclusions: Rates of VZV infections in" exact="fingolimod" post="clinical trials were low with fingolimod 0.5 mg, but"/>
 <result pre="of VZV infections in fingolimod clinical trials were low with" exact="fingolimod" post="0.5 mg, but higher than in placebo recipients. VZV"/>
 <result pre="with progressive multifocal leukoencephalopathy (PML), whose risk increases after 24" exact="natalizumab" post="administrations. Objectives: To evaluate the efficacy of different available"/>
 <result pre="rate (ARR) and magnetic resonance imaging (MRI) activity after 24" exact="natalizumab" post="doses, in patients with RR-MS. Methods: Spontaneous, prospective, multicenter,"/>
 <result pre="statistical analyses conducted according to: 1) the decision to continue/discontinue" exact="natalizumab" post="after 24 doses [intention-to-treat (ITT) population]; 2) the treatment"/>
 <result pre="the &quot;AT&quot; population the distribution of patients was: 1)patients continuing" exact="natalizumab" post="during the year of follow-up (CONTINUERS); 2)patients discontinuing natalizumab"/>
 <result pre="continuing natalizumab during the year of follow-up (CONTINUERS); 2)patients discontinuing" exact="natalizumab" post="during the year of follow up (QUITTERS); 3)patients switching"/>
 <result pre="of follow up (QUITTERS); 3)patients switching among different therapies, including" exact="natalizumab" post="(SWITCHERS). No significant differences in demographic and baseline clinical"/>
 <result pre="and radiological (p=0.018) activity was significantly lower in patients continuing" exact="natalizumab" post="(N=43) than in those stopping it (N=81) This meant"/>
 <result pre="those stopping it (N=81) This meant a protective effect of" exact="natalizumab" post="continuation on clinical activity (odds ratio (OR),0.33; 95% confidence"/>
 <result pre="Clinical and MRI reactivation occurs more frequently in patients stopping" exact="natalizumab" post="than in those continuing it. Therapy discontinuation should be"/>
 <result pre="benefits of continuing the drug. P864 Risk of relapse after" exact="natalizumab" post="discontinuation: which is the best treatment option? P Iaffaldano"/>
 <result pre="best treatment option for reducing the relapse risk occurring after" exact="natalizumab" post="(NTZ) discontinuation in Multiple Sclerosis (MS) patients. Objectives: To"/>
 <result pre="before NTZ. Patients who started, after NTZ, a treatment with" exact="fingolimod" post="(FIN) or with other DMDs were propensity score (PS)-matched"/>
 <result pre="MD, United States Background: Multiple sclerosis (MS) patients treated with" exact="natalizumab" post="are at risk for developing Progressive Multifocal Leukoencephalopathy (PML),"/>
 <result pre="JCV from CSF needs further investigation. P867 Long-term safety of" exact="rituximab" post="in MS and other autoimmune disorders E Bernitsas 1,"/>
 <result pre="incidence of infections and malignancies in patients who received continuous" exact="rituximab" post="therapy for at least 3 years. Methods: This was"/>
 <result pre="malignancies in patients who received 6 monthly intravenous cycles of" exact="rituximab" post="infusions continuously for at least 3 years. Results: 23"/>
 <result pre="Results: 23 patients (mean age 40 years) received continuous 6-monthly" exact="rituximab" post="infusions for a period ranging from 36 to 72"/>
 <result pre="MS patients (mean age: 41 years) receiving interferon beta or" exact="glatiramer acetate" post="therapy observed for 3 years, served as control group."/>
 <result pre="the two groups. Four serious infections (requiring hospitalization) in the" exact="rituximab" post="and 7 in the control group were observed (p=ns)."/>
 <result pre="the observation period ranging up to 72 months in the" exact="rituximab" post="group and 36 months in the control group. Pre"/>
 <result pre="and 36 months in the control group. Pre and post" exact="rituximab" post="showed remarkable reduction in disease activity. Efficacy data will"/>
 <result pre="infections with prolonged peripheral B-cell depletion in patients who received" exact="rituximab" post="infusions for up to 6 years continuously. While encouraging,"/>
 <result pre="countries for relapsing-remitting multiple sclerosis (RRMS). In 3 clinical trials," exact="alemtuzumab" post="demonstrated superior efficacy vs subcutaneous interferon-beta-1a (SC IFNB-1a) with"/>
 <result pre="Annual malignancy rates during controlled studies were the same for" exact="alemtuzumab" post="and SC IFNB-1a (0.003 events/year),including rates for basal cell"/>
 <result pre="alemtuzumab-treated patients in the MS clinical trial program. Methods: The" exact="alemtuzumab" post="MS clinical trial program included the CAMMS223 phase 2"/>
 <result pre="studies, and an ongoing extension (NCT00930553). Patients were randomized to" exact="alemtuzumab" post="12 mg (and 24 mg in CAMMS223 and CARE-MS"/>
 <result pre="the first year of the CARE-MS extension, 1486 patients received" exact="alemtuzumab" post="in the MS clinical trial program (median follow-up 53.4"/>
 <result pre="by number of treatment courses, years of follow-up, or cumulative" exact="alemtuzumab" post="dose (overall SIR 1.27; 95% CI 0.85-1.92). Thyroid papillary"/>
 <result pre="1.93; 95% CI 0.48-7.72). Conclusions: The risk of malignancies with" exact="alemtuzumab" post="in the MS clinical trial program was not greater"/>
 <result pre="natalizumab-treated MS patient three and a half (3,5) months after" exact="natalizumab" post="discontinuation. Methods: A 37-year-old female, diagnosed with MS in"/>
 <result pre="for eight years. Due to a high number of relapses" exact="natalizumab" post="was initiated and the patient’s condition stabilized for 2,5"/>
 <result pre="infections. The patient’s condition was stable for three months after" exact="natalizumab" post="discontinuation and only complained of extreme fatigue and weight"/>
 <result pre="lesions compatible with MS. Three and a half months after" exact="natalizumab" post="discontinuation the patient exhibited marked deterioration with vomiting, vertigo,"/>
 <result pre="IV and per os) as well as immunomodulatory treatment with" exact="glatiramer acetate" post="and approximately 8 months later her condition has stabilized"/>
 <result pre="remain vigilant for PML or IRIS manifestations even after the" exact="natalizumab" post="washout period. P871 Evidence of cortical lesions in PML"/>
 <result pre="distinguish PML from MS cortical lesions. P872 Application of serum" exact="natalizumab" post="levels during plasma exchange in multiple sclerosis patients with"/>
 <result pre="Progressive multifocal leukoencephalopathy (PML) is a serious adverse event of" exact="natalizumab" post="treatment. Restoring immune function by plasmapheresis (PLEX) is important"/>
 <result pre="the optimal treatment strategy. Objectives: To evaluate if measuring serum" exact="natalizumab" post="levels before and during PLEX may optimize the current"/>
 <result pre="sclerosis (MS) patients who developed natalizumab-associated PML we measured serum" exact="natalizumab" post="concentrations at the time of the diagnosis of PML"/>
 <result pre="The required number of PLEX treatments to reach subtherapeutic serum" exact="natalizumab" post="concentrations (below 1 µg/mL) depended on the serum natalizumab"/>
 <result pre="serum natalizumab concentrations (below 1 µg/mL) depended on the serum" exact="natalizumab" post="concentration at the time of PML diagnosis. The number"/>
 <result pre="between 4 and 7 in these patients. Conclusions: Measuring serum" exact="natalizumab" post="concentrations before and during PLEX might be helpful to"/>
 <result pre="of natalizumab. P873 Rituximab in high activity MS patients after" exact="natalizumab" post="withdrawal L Rodriguez Esparragoza 1, A Vinagre 1, B"/>
 <result pre="activity in MS patients with suboptimal response to immunomodulators. When" exact="natalizumab" post="is withdrawn, it is customary to associate fingolimod, with"/>
 <result pre="MRI variables of a group of patients previously treated with" exact="natalizumab" post="and most of them with fingolimod, who had received"/>
 <result pre="natalizumab and most of them with fingolimod, who had received" exact="rituximab" post="due to persistent relapse activity. Methods: Ten patients were"/>
 <result pre="EDSS was 3.1. All but 2 had been treated with" exact="fingolimod" post="after natalizumab withdrawal (in one case due to lack"/>
 <result pre="3.1. All but 2 had been treated with fingolimod after" exact="natalizumab" post="withdrawal (in one case due to lack of drug"/>
 <result pre="A single patient, with a high annualized relapse rate before" exact="natalizumab" post="had one relapse. No new T2 lesions or contrast"/>
 <result pre="new humanized and humane anti CD-20 monoclonal antibodies have replaced" exact="rituximab" post="in ongoing clinical trials. Rituximab has been available in"/>
 <result pre="reasonable risk/benefit balance. P874 Life threatening asthmatic crisis after prolonged" exact="fingolimod" post="treatment M Caporro 1, C Gobbi 1, C Zecca"/>
 <result pre="investigating smaller cohorts. P876 Two-years clinical and radiological activity during" exact="fingolimod" post="post-natalizumab in relapsing-remitting multiple sclerosis. Single-center experience R Hernández-Clares"/>
 <result pre="Clinical Universitary Hospital, Neurorradiology Department, Murcia, Spain Background: Until 2011," exact="natalizumab" post="(NTZ) was the treatment of choice in patients with"/>
 <result pre="NTZ) and at 3, 6, 12 and 24 months after" exact="fingolimod" post="initiation; laboratory values were determined at baseline, 1 month"/>
 <result pre="persistent lymphopenia. There were no treatment discontinuations. Mean time on" exact="fingolimod" post="was 24.6 months. The ARR was 0.11, and EDSS"/>
 <result pre="associated with clinical and radiological relapse. Our experience suggests that" exact="fingolimod" post="is an effective alternative option for controlling disease activity"/>
 <result pre="to assess disease state stability, efficacy, and tolerability in a" exact="natalizumab" post="to dimethyl fumarate crossover design JF Foley 1, T"/>
 <result pre="Physician Specialists, Salt Lake City, UT, United States Background: While" exact="natalizumab" post="therapy is highly efficacious for the treatment of multiple"/>
 <result pre="leukoencephalopathy (PML) in patients who have an immunosuppressant history, &amp;gt;=24" exact="natalizumab" post="doses, and JCV index of &amp;gt;=1.5. A crossover to"/>
 <result pre="for 24 weeks in patients who have crossed over from" exact="natalizumab" post="to dimethyl fumarate therapy. Methods: 30 subjects at high"/>
 <result pre="on therapy, JCV index &amp;gt;= 1.5) for developing PML on" exact="natalizumab" post="were enrolled in a study to monitor their transition"/>
 <result pre="observed for 24 weeks, starting from their last dose of" exact="natalizumab" post="therapy. Outcome measures included disease stability defined by EDSS,"/>
 <result pre="mean MS disease duration was 16 years, mean number of" exact="natalizumab" post="infusions was 67, and the mean length of the"/>
 <result pre="P878 High seroconversion in a cohort MS patients treated with" exact="natalizumab" post="in Amsterdam A Vennegoor 1, JA Rossum 1, MP"/>
 <result pre="factor for the development of progressive multifocal leukoencephalopathy (PML) during" exact="natalizumab" post="treatment in multiple sclerosis (MS) patients. It has been"/>
 <result pre="who are initially tested seronegative can convert to seropositive during" exact="natalizumab" post="treatment. Objectives: The aim of the present study was"/>
 <result pre="to evaluate the rate of conversion in MS patients during" exact="natalizumab" post="treatment. Methods: Between March 2007 and July 2013, 168"/>
 <result pre="Between March 2007 and July 2013, 168 MS patients started" exact="natalizumab" post="in the MS Center of the VU Medical Center"/>
 <result pre="Conclusions: The seroconversion rates in our MS patients treated with" exact="natalizumab" post="are higher than published until now. This incidence of"/>
 <result pre="higher than published until now. This incidence of seroconversion in" exact="natalizumab" post="treated MS patients appears to be much higher than"/>
 <result pre="general population. This might indicate a higher vulnerability due to" exact="natalizumab" post="treatment. P879 Disability progression associated with transitioning treatment after"/>
 <result pre="P879 Disability progression associated with transitioning treatment after 2-years of" exact="natalizumab" post="therapy as reported by NARCOMS participants AR Salter 1,"/>
 <result pre="consequences of transitioning to another treatment after 2 years of" exact="natalizumab" post="(NAT) have not been fully determined. Objectives: To retrospectively"/>
 <result pre="in NARCOMS participants who remained on NAT or transitioned to" exact="fingolimod" post="(FIN) or injectable therapies (INJ) after 2 years of"/>
 <result pre="relapsing-remitting multiple sclerosis (RRMS). Alemtuzumab demonstrated superior efficacy over subcutaneous" exact="interferon beta-1a" post="and manageable safety in the 2-year, phase 3 CARE-MS"/>
 <result pre="during clinical development. Objectives: To report incidence and severity of" exact="alemtuzumab" post="IARs during 3-year follow-up of the pooled CARE-MS studies,"/>
 <result pre="on prior therapy [CARE-MS II; NCT00548405]) received intravenous infusions of" exact="alemtuzumab" post="12 mg/day on 5 consecutive days at baseline and"/>
 <result pre="and on 3 consecutive days 12 months later, and as-needed" exact="alemtuzumab" post="re-treatment in an ongoing extension study (NCT00930553). IARs were"/>
 <result pre="in each treatment course. Results: 811 patients were treated with" exact="alemtuzumab" post="in the core studies; 742 entered the extension. Over"/>
 <result pre="in Course 3 (62.9%). IAR frequency was highest with initial" exact="alemtuzumab" post="exposure and generally decreased with each infusion day. IARs"/>
 <result pre="of anaphylaxis occurred during Course 3 and resolved with treatment;" exact="alemtuzumab" post="treatment was discontinued. Effective IAR management included practices before"/>
 <result pre="required infusion interruption or adjustment. Conclusions: IARs were common with" exact="alemtuzumab" post="but were predominantly mild or moderate and decreased with"/>
 <result pre="a risk factor for progressive multifocal leukoencephalopathy (PML) development in" exact="natalizumab" post="(NTZ)-treated multiple sclerosis (MS) patients. According to recent studies"/>
 <result pre="P884 Disease reactivation in multiple sclerosis pregnant women who stopped" exact="natalizumab" post="during the first gestational period M Rodegher 1, MJ"/>
 <result pre="childbearing. Pregnancies in women with severe relapsing-remitting MS treated with" exact="natalizumab" post="(NAT) currently constitute a major challenge for the risk"/>
 <result pre="GW. P885 Multiple sclerosis as immune related adverse event after" exact="ipilimumab" post="treatment in metastatic melanoma LA Gerdes 1, A Junker"/>
 <result pre="Shortly later cerebral MRI showed a new T2-lesion. Chemotherapy with" exact="paclitaxel" post="and carboplatin followed, but due to ongoing tumor disease"/>
 <result pre="cerebral MRI showed a new T2-lesion. Chemotherapy with paclitaxel and" exact="carboplatin" post="followed, but due to ongoing tumor disease IPI was"/>
 <result pre="sera has become a routine procedure in PML-risk stratification before/under" exact="natalizumab" post="(Tysabri®, Biogen Idec) treatment. Beside qualitative JCV-status, quantitative index"/>
 <result pre="Kingdom Background: A large phase III trial (CLARITY) of oral" exact="cladribine" post="(Movectro) in people with relapsing multiple sclerosis (pwRMS) reported"/>
 <result pre="(pwRMS) reported significant efficacy. However, concerns over the safety of" exact="cladribine" post="have been raised by American and European regulatory bodies."/>
 <result pre="suspected increased cancer risk was key for the rejection of" exact="cladribine" post="for pwRMS by the European Medicines Agency (EMA) in"/>
 <result pre="assess cancer risk. Objectives: We compared the cancer risk of" exact="cladribine" post="in CLARITY with other disease-modifying therapies (DMTs) used in"/>
 <result pre="in these trials were cladribine, dimethyl fumarate, fingolimod, teriflunomide, natalizumab," exact="alemtuzumab" post="and glatiramer acetate. The seven studies comparing treatment versus"/>
 <result pre="trials were cladribine, dimethyl fumarate, fingolimod, teriflunomide, natalizumab, alemtuzumab and" exact="glatiramer acetate." post="The seven studies comparing treatment versus placebo (as opposed"/>
 <result pre="lower than in the recently reported phase III trial of" exact="cladribine" post="in people with clinically isolated syndrome suggestive of demyelination"/>
 <result pre="groups of CLARITY and ORACLE (p=1). Conclusions: Our study suggests" exact="cladribine" post="in doses used in CLARITY and ORACLE does not"/>
 <result pre="risk of all DMTs. Given its efficacy, tolerability and convenience" exact="cladribine" post="should be reconsidered for treatment of pwRMS. P888 Fingolimod"/>
 <result pre="should be reconsidered for treatment of pwRMS. P888 Fingolimod after" exact="natalizumab" post="- Is there a rebound of MS activity? IB"/>
 <result pre="10 ys, EDSS 6.0) who earlier had no effect on" exact="glatiramer acetate" post="and methylprednisolone (MP) treatment; 2 nd - with SP"/>
 <result pre="6.0) who earlier had no effect on glatiramer acetate and" exact="methylprednisolone" post="(MP) treatment; 2 nd - with SP with relapses"/>
 <result pre="new safety concerns identified over 4 years’ follow-up. P906 Prolonged-release" exact="fampridine" post="enhances physical activity during everyday life in patients with"/>
 <result pre="Zurich, Department of Neurology, Zurich, Switzerland Background: Treatment with prolonged-release" exact="fampridine" post="has shown beneficial effects on walking ability in a"/>
 <result pre="endurance and coordination were found to be improved by prolonged-release" exact="fampridine" post="(FAMPKIN-study; NCT01576354). Objectives: In the present sub-study of FAMPKIN,"/>
 <result pre="In the present sub-study of FAMPKIN, we were interested whether" exact="fampridine" post="influences the physical activity of patients with MS in"/>
 <result pre="weeks each), in which the patients were either treated with" exact="fampridine" post="(10mg twice daily) or placebo. Patients were equipped with"/>
 <result pre="during both treatment phases. The study population was classified into" exact="fampridine" post="responders (n=17) and non-responders (n=30) based on criteria defined"/>
 <result pre="colleagues (Lancet, 2009). Results: Physical activity was not altered by" exact="fampridine" post="in the total study population (n=55). In contrast, the"/>
 <result pre="the total study population (n=55). In contrast, the group of" exact="fampridine" post="responders revealed a significant increase in the summated daily"/>
 <result pre="activity during the waking phase was not different between the" exact="fampridine" post="and placebo treatment phase for any group, thus implying"/>
 <result pre="rather than the time of activity is primarily modified by" exact="fampridine" post="in patients with MS. Conclusions: These results demonstrate for"/>
 <result pre="MS. Conclusions: These results demonstrate for the first time that" exact="fampridine" post="is able to enhance the physical activity of patients"/>
 <result pre="everyday life. This data emphasizes the clinical relevance of the" exact="fampridine" post="treatment for daily living of patients with MS-associated gait"/>
 <result pre="anti-spastic therapies. Previous studies demonstrated the beneficial effect of prolonged-release" exact="fampridine" post="on walking speed in patients with MS. Objectives: We"/>
 <result pre="the gait pattern which underlie the improved walking function under" exact="fampridine" post="treatment. Methods: Many gait parameters of coordination, stability and"/>
 <result pre="weeks), in which patients were treated either with placebo or" exact="fampridine" post="(twice daily 10mg). According to the criteria defined by"/>
 <result pre="test [TUG]) showed an improved gait performance during treatment with" exact="fampridine" post="as compared to placebo. This effect was augmented in"/>
 <result pre="motion of the trunk during walking was smaller during the" exact="fampridine" post="treatment, implying an increased dynamic stability. Conclusions: The kinematic"/>
 <result pre="dynamic stability. Conclusions: The kinematic and kinetic data imply that" exact="fampridine" post="induces differential gait modifications that are likely to depend"/>
 <result pre="the gait pattern underlie the clinical improvement induced by the" exact="fampridine" post="treatment. P909 Clinical features of patients presenting with seizures"/>
 <result pre="future work. P911 Detailed characterization of the effects of prolonged-release" exact="fampridine" post="on walking function in patients with multiple sclerosis (FAMPKIN)"/>
 <result pre="Zurich, Switzerland Background: Recent studies demonstrated the beneficial effects of" exact="fampridine" post="(4-aminopyridine) on gait velocity in a subset of patients"/>
 <result pre="( http://clinicaltrials.gov) aimed to characterize the effects of prolonged-release (PR)" exact="fampridine" post="on different modalities of ambulatory function including muscle strength,"/>
 <result pre="and placebo-controlled cross-over study assessed gait function during two double-blind" exact="fampridine" post="or placebo treatment phases (each 6 weeks). Methods: Walking"/>
 <result pre="(n=5) met the responder criteria in both phases. Results: During" exact="fampridine" post="treatment, gait velocity (timed-25-foot walk) was increased by 5.8%"/>
 <result pre="each patient. Conclusions: The present study demonstrates beneficial effects of" exact="fampridine" post="on different aspects of locomotion and indicates the clinical"/>
 <result pre="ferritin, free T3, free T4, TSH, creatinine, vitamin B12 and" exact="folic acid" post="values of patients for last 6 months were taken"/>
 <result pre="particularly when a drug is used off-license. P918 Effect of" exact="fampridine" post="(4-aminopyridine) on the manual functions of patients with multiple"/>
 <result pre="ambulatory deficits. Anecdotal evidences concerning the possible therapeutic effects of" exact="fampridine" post="on manual abilities of patients with MS (PwMS) raise"/>
 <result pre="need for thorough investigation. Objectives: To assess the effect of" exact="fampridine" post="on manual functions of PwMS. Methods: 17 Relapsing Remitting"/>
 <result pre="suggest that in addition to the known beneficial effects of" exact="fampridine" post="on ambulation, also improvement of manual functions, in terms"/>
 <result pre="in functional impairment in persons with multiple sclerosis treated with" exact="dalfampridine" post="AC Lo 1,2,3, JA Ruiz 1, BM Anderson 1,"/>
 <result pre="quality of life in persons with multiple sclerosis (pwMS). Although" exact="dalfampridine" post="extended release (D-ER) has been available for clinical use"/>
 <result pre="life (QoL). Objectives: To evaluate the impact of prolonged-release (PR)" exact="fampridine" post="tablet (dalfampridine extended release in US) on self-assessed walking"/>
 <result pre="and balance. P923 The effectiveness and safety of the intrathecal" exact="baclofen" post="for the multiple sclerosis-related spasticity S Gatzonis 1, K"/>
 <result pre="aim to present our 14-year experience on implementing the intrathecal" exact="baclofen" post="therapy (ITB) for the symptomatic treatment of spasticity in"/>
 <result pre="of 50mcg baclofen. A pump for the intrathecal administration of" exact="baclofen" post="was implanted to the patients who responded favorably to"/>
 <result pre="was implanted to the patients who responded favorably to the" exact="baclofen" post="trial. (Medstream, Depuy Synthes; Synchromed II, Medtronic) (Archimedes, Codman;"/>
 <result pre="was 2.86 (range 2-4), the mean best MAS after the" exact="baclofen" post="trial was 1.18. Data presented here concern 14 patients"/>
 <result pre="criteria. The mean post-op MAS was 0.375. The mean final" exact="baclofen" post="dose was 104 mcg/24h (range: 30-320). An average of"/>
 <result pre="Three patients were reoperated for hardware related complications. Conclusions: Intrathecal" exact="baclofen" post="is a viable option for the symptomatic treatment of"/>
 <result pre="quality of life (QoL) in multiple sclerosis (MS). Prolonged-release (PR)" exact="fampridine" post="tablet (dalfampridine extended release in the United States) is"/>
 <result pre="satisfaction for people living with MS. P929 Long-term effects of" exact="fampridine" post="on walking ability in patients with multiple sclerosis: a"/>
 <result pre="II core study (FAMPKIN), preceding the present study, showed that" exact="fampridine" post="not only improved walking speed, but also other aspects"/>
 <result pre="present study (FAMPKIN-EXT) aimed to investigate the long-term effects of" exact="fampridine" post="on ambulatory performance in patients with MS. Methods: 53"/>
 <result pre="9.2 years; EDSS 5.3 +/- 1.2) and treated with prolonged-release" exact="fampridine" post="(10mg twice daily; open-label). The results presented here include"/>
 <result pre="study (Screening (S), no fampridine), after 11.5 months of continuous" exact="fampridine" post="treatment (V2), and after a 2 week washout period"/>
 <result pre="improvement in self-reported walking ability after 11.5 month of continuous" exact="fampridine" post="treatment (S: 38.4 +/- 1.8 pts; V2: 33.4 +/-"/>
 <result pre="V2 vs. V3, P&amp;lt; 0.001). The beneficial long-term effects of" exact="fampridine" post="assessed with clinical gait tests were accompanied by specific"/>
 <result pre="gait analysis. Conclusions: FAMPKIN-EXT demonstrated positive long-term effects of prolonged-release" exact="fampridine" post="in patients with MS. P930 II. A multi-center investigation"/>
 <result pre="Neurology, Colmar, France, 5alSacEP Network, Neurology, Hagenau, France Background: Prolonged-release" exact="fampridine" post="(Fampyra ®) is an oral form of the potassium"/>
 <result pre="product is available in clinical practice. The efficiency of the" exact="fampridine" post="for every patient is expressed in walking time to"/>
 <result pre="in the clinical trials. P933 Long -term treatment of intrathecal" exact="baclofen" post="in multiple sclerosis: frequency and severity of withdrawal syndrome"/>
 <result pre="frequent disabling symptom in patients with multiple sclerosis (MS). Intrathecal" exact="baclofen" post="(ITB) delivered by programmable pump devices represents an important"/>
 <result pre="with vital functions at emergency unit and immediately received oral" exact="baclofen" post="and parenteral diazepam. ITB withdrawal syndrome occurred once per"/>
 <result pre="be further investigated. Ruck T et al. Long-term effects of" exact="dalfampridine" post="in patients with multiple sclerosis. J Neurol Sci 2014;"/>
 <result pre="have a positive impact on patients’ QOL. P939 Sustained release" exact="fampridine" post="treatment impacts on the daily physical activity amount in"/>
 <result pre="Clínico Universitario de Valladolid, Hospital Pharmacy, Valladolid, Spain Background: Sustained-release" exact="fampridine" post="(fampridine-SR) is the first drug approved for the improvement"/>
 <result pre="areas in CNS. P941 Effects of long-term treatment with prolonged-release" exact="fampridine" post="on cognitive functioning in patients with multiple sclerosis SD"/>
 <result pre="the EXTENSION described here, we found that treatment with prolonged-release" exact="fampridine" post="(4-aminopyridine), a potassium-channel blocker, is associated with improvements in"/>
 <result pre="is to study neuropsychological functions in patients with MS under" exact="fampridine" post="therapy. Methods: 32 MS subjects of FAMPKIN EXTENSION were"/>
 <result pre="and fatigue. Tests were administered during continuous treatment with prolonged-release" exact="fampridine" post="(V2), and within a 2 week treatment-free interval (V3)."/>
 <result pre="Mdn=13.00, z=−2.80, p&amp;lt; 0.05), always indicating better test performance under" exact="fampridine" post="therapy. These cognitive effects were paralleled by patients’ perception"/>
 <result pre="V3: Mdn=14.00, z=−2.57, p&amp;lt; 0.05). Conclusions: Our data show that" exact="fampridine" post="PR therapy positively impacts cognitive performance in MS patients"/>
 <result pre="psychomotor speed and executive function skills. These findings suggest that" exact="fampridine" post="PR may reduce fatigue in this patient population. P942"/>
 <result pre="patients were treated with interferon beta, the other 11 -" exact="glatiramer acetate," post="18 -mitoxantrone and 6 with natalizumab. All patients completed"/>
 <result pre="Neurology, Winnipeg, MB, Canada Background: A clinical trial of oral" exact="testosterone" post="to treat multiple sclerosis-related fatigue (MSRF) demonstrated a high"/>
 <result pre="a high rate of screen failures due to low baseline" exact="testosterone" post="levels, something not previously characterized in this population. Objectives:"/>
 <result pre="This study was designed to determine the frequency of low" exact="testosterone" post="and low-normal testosterone levels in male MS patients and"/>
 <result pre="designed to determine the frequency of low testosterone and low-normal" exact="testosterone" post="levels in male MS patients and assess if testosterone"/>
 <result pre="low-normal testosterone levels in male MS patients and assess if" exact="testosterone" post="levels correlate with self-reported fatigue. Methods: Screening data from"/>
 <result pre="self-reported fatigue. Methods: Screening data from a clinical trial of" exact="testosterone" post="for MSRF were used and consecutive male patients were"/>
 <result pre="consecutive male patients were recruited during clinic visits. Patients on" exact="testosterone" post="or anti-androgen therapy or with a relapse in the"/>
 <result pre="(1) determine the percentage of patients with low or low-normal" exact="testosterone" post="levels and (2) detect any correlation between testosterone level"/>
 <result pre="or low-normal testosterone levels and (2) detect any correlation between" exact="testosterone" post="level and MSRF as measured by either the Modified"/>
 <result pre="visual analog scale (VAS). Exploratory outcomes assessed for associations with" exact="testosterone" post="levels were age, type/duration of MS, disease severity (Expanded"/>
 <result pre="using the standard MSIF cutoff. After accounting for other covariates," exact="testosterone" post="levels were not associated with MSRF (partial-regression coefficients -0.594,"/>
 <result pre="While an interim analysis does not demonstrate any association between" exact="testosterone" post="and MSRF, recruitment is ongoing and final results will"/>
 <result pre="of the completed dataset will determine if low or low-normal" exact="testosterone" post="levels are associated with fatigue or any other demographic"/>
 <result pre="were significantly increased only in the Mobilizer patient after two" exact="natalizumab" post="infusions compared to baseline (p&amp;lt; 0.05); among the total"/>
 <result pre="IL-2Rβγ-signaling contributes to regulatory T cell maintenance and stability in" exact="daclizumab" post="HYP-treated RRMS patients DJ Huss 1, DS Mehta 2,"/>
 <result pre="using IFN-beta-1b and were randomized to add-on treatment with either" exact="cholecalciferol" post="20000IU/week or placebo. Concentrations of LAP (TGF-beta-1a), INF-γ, IL-2,"/>
 <result pre="do Treg cell function and related cytokines levels change in" exact="alemtuzumab" post="treated patients? A 24 months immunological study S De"/>
 <result pre="functional analysis; cytokine, chemokine, and chemokine receptor mRNA levels after" exact="alemtuzumab" post="in RRMS:24-months follow-up. Methods: Multicenter 24 months follow-up of"/>
 <result pre="myelin basic protein (MBP) or anti-CD3-CD28. Timepoints: Baseline (before first" exact="alemtuzumab" post="course);Month (M) 6, M12, M18, M24: respectively 6,12,18, 24"/>
 <result pre="24 months after the first course. M12 was before second" exact="alemtuzumab" post="course. The relative mean difference between baseline and subsequent"/>
 <result pre="could provide information on the timing of subsequent courses of" exact="alemtuzumab" post="in individual patients. P957 Fingolimod selectively affect antigen-presenting cells"/>
 <result pre="Objectives: To present the proposed mechanism of action (MoA) of" exact="teriflunomide" post="based on in vitro, preclinical and clinical data. Methods:"/>
 <result pre="responses to cognate peptide variants in the presence/absence of various" exact="teriflunomide" post="concentrations; teriflunomide impact in a rat experimental autoimmune encephalomyelitis"/>
 <result pre="cognate peptide variants in the presence/absence of various teriflunomide concentrations;" exact="teriflunomide" post="impact in a rat experimental autoimmune encephalomyelitis (EAE) model"/>
 <result pre="pivotal clinical trials in patients with MS. Results: In vitro," exact="teriflunomide" post="inhibited proliferation of human T and B cells stimulated"/>
 <result pre="cells. Our observations provide insight into the mechanism by which" exact="teriflunomide" post="treatment reduces disease severity while preserving protective immunity in"/>
 <result pre="P960 Enhanced axonal metabolism in multiple sclerosis patients treated with" exact="natalizumab" post="OT Wiebenga 1,2, AM Klauser 2, MM Schoonheim 2,"/>
 <result pre="relapses. Previous spectroscopy studies have shown that patients treated with" exact="interferon beta-1b" post="(IFNb) or glatiramer acetate (GA) have increased total N-acetylaspartate"/>
 <result pre="have shown that patients treated with interferon beta-1b (IFNb) or" exact="glatiramer acetate" post="(GA) have increased total N-acetylaspartate over total creatine (tNAA/tCr)"/>
 <result pre="N-acetylaspartate over total creatine (tNAA/tCr) ratios, whereas the effect of" exact="natalizumab" post="on brain metabolite concentrations remains unknown. Objectives: To investigate"/>
 <result pre="concentrations remains unknown. Objectives: To investigate the longitudinal effect of" exact="natalizumab" post="on absolute concentrations of brain metabolites in RRMS patients"/>
 <result pre="magnetic resonance spectroscopic imaging (MRSI). Methods: 25 RRMS patients initiating" exact="natalizumab" post="treatment were included and scanned every six months for"/>
 <result pre="compared to NAWM and additionally lower Glu in LWM of" exact="natalizumab" post="patients. In natalizumab patients only, significant metabolite increases were"/>
 <result pre="and additionally lower Glu in LWM of natalizumab patients. In" exact="natalizumab" post="patients only, significant metabolite increases were found for LWM"/>
 <result pre="and the healthy control group. Conclusions: Only patients treated with" exact="natalizumab" post="showed an increase in tNAA, tCr and Glu in"/>
 <result pre="effect of natalizumab. P961 Characterization of CD56bright NK cells in" exact="daclizumab" post="HYP-treated RRMS patients DJ Huss 1, MF Fragoso 1,"/>
 <result pre="of circulating CD39-expressing T regulatory cells from MS patients by" exact="fingolimod" post="V van Pesch 1,2, N Muls 2, CJM Sindic"/>
 <result pre="were collected from healthy controls and RRMS patients before starting" exact="fingolimod" post="therapy and 3 months after treatment initiation. Natural Treg"/>
 <result pre="reduced. The proportion of CD39 + Tregs was increased by" exact="fingolimod" post="but not of CD39 +CD4 +Foxp3 - T cells."/>
 <result pre="effect is purely related to the cellular redistribution mediated by" exact="fingolimod" post="or could be due to interference with sphingosine-1-P receptor"/>
 <result pre="of cytokines including TNFα, IL-6, IFNα, IL-12 and IL-23, inducible" exact="nitric oxide" post="synthase, the matrix metalloproteases MMP7 and MMP10, and the"/>
 <result pre="so far. Objectives: To study the effects of interferon (IFN)-beta," exact="glatiramer acetate" post="(GA), natalizumab (Nat) and fingolimod (Fingo) on the expression"/>
 <result pre="To study the effects of interferon (IFN)-beta, glatiramer acetate (GA)," exact="natalizumab" post="(Nat) and fingolimod (Fingo) on the expression of the"/>
 <result pre="effects of interferon (IFN)-beta, glatiramer acetate (GA), natalizumab (Nat) and" exact="fingolimod" post="(Fingo) on the expression of the T cell receptor"/>
 <result pre="in microglia activation measured by [11C]PK11195-PET in patients treated with" exact="natalizumab" post="A Maoz 1, E Monohan 1, P Kothari 1,"/>
 <result pre="capacity of peripherally derived immune cells. However, the effect of" exact="natalizumab" post="on innate immune inflammatory burden in within the CNS"/>
 <result pre="within the CNS is unknown. Objectives: To determine the effect" exact="natalizumab" post="on whole-brain binding of [C11]-PK11195 as well as within"/>
 <result pre="and 6 months of treatment. Methods: Twelve RRMS patients starting" exact="natalizumab" post="therapy were included in the study. Dynamic images of"/>
 <result pre="region was completed in 10 patients. After the start of" exact="natalizumab" post="treatment, half of the patients (5) demonstrated a significant"/>
 <result pre="the second sample two days later after having started intravenous" exact="methylprednisolone" post="(1000 mg/d) therapy. At least four weeks after relapse,"/>
 <result pre="1) and patients in remission (sample 3). However, treatment with" exact="methylprednisolone" post="(sample 2) yielded 1908 genes significantly regulated as compared"/>
 <result pre="MicroRNA expression in monocytes of relapsing-remitting MS patients treated with" exact="fingolimod" post="CS Moore 1, BA Durafourt 1, P Giacomini 1,"/>
 <result pre="The objective of the present study was to determine how" exact="fingolimod" post="could influence miRNA expression in circulating monocytes of MS"/>
 <result pre="whether these results were due to a direct effect of" exact="fingolimod" post="on human monocytes, CD14+ cells were isolated from healthy"/>
 <result pre="subjects, pre-exposed to fingolimod, and stimulated with LPS. Ex vivo," exact="fingolimod" post="did not alter the LPS-induced changes in miRNA expression."/>
 <result pre="expression. Conclusions: These findings suggest that the mechanism by which" exact="fingolimod" post="normalized miRNA levels in vivo was not due to"/>
 <result pre="a result of decreased circulating pro-inflammatory lymphocytes. P968 Effect of" exact="natalizumab" post="treatment on circulating CD4+CD62L+ T-cells in multiple sclerosis patients"/>
 <result pre="valuable tool to personalize NTZ therapy. P969 Distinct effects of" exact="fingolimod" post="on gene expression of T-cell subsets in the blood"/>
 <result pre="the gene expression patterns of T cells before and during" exact="fingolimod" post="treatment in order to better understand the molecular mechanisms"/>
 <result pre="patients with relapsing-remitting MS at 3 different time points: before" exact="fingolimod" post="treatment initiation (baseline) as well as after 24 hours"/>
 <result pre="are affected in both T cell subsets. Conclusions: Treatment with" exact="fingolimod" post="leads to a marked reduction of lymphocytes in the"/>
 <result pre="P970 Immunoglobulin family genes are associated with clinical response to" exact="natalizumab" post="M Gurevich 1, G Miron 1, E Hanael 1,"/>
 <result pre="management of Natalizumab treated RRMS patients. P971 Differential effects of" exact="fingolimod" post="and copaxone upon FoxP3+ regulatory B-cells in MS C"/>
 <result pre="decreased at 3 and 6-months p=0.05 and 0.03, respectively for" exact="fingolimod" post="and p=0.02 and 0.05, respectively for Copaxone. By contrast,"/>
 <result pre="higher proportions of CD19+CD25+FoxP3+ was also apparent at 3-month of" exact="fingolimod" post="(p=0.06). The Copaxone did not show any changes in"/>
 <result pre="Conclusions: Our data may extend on the different mechanisms of" exact="fingolimod" post="and copaxone in MS immunoregulation. P972 Rapid, sustained and"/>
 <result pre="the inflammatory response in patients with MS. P976 Effects of" exact="alemtuzumab" post="on selective immune cell subsets in the blood of"/>
 <result pre="of Clinical Neuroscience, Dresden, Germany Background: The monoclonal anti-CD52 antibody" exact="alemtuzumab" post="mediates antibody and complement-depending cytotoxicity. The application of alemtuzumab"/>
 <result pre="antibody alemtuzumab mediates antibody and complement-depending cytotoxicity. The application of" exact="alemtuzumab" post="results in an altered distribution of different immune cell"/>
 <result pre="recovery of particular cell subtypes. Objectives: To evaluate effects of" exact="alemtuzumab" post="on different immune cell subtypes in multiple sclerosis patients."/>
 <result pre="12 relapsing-remitting multiple sclerosis patients were drawn before and after" exact="alemtuzumab" post="infusion including baseline, month (M) 3, M6, M9, M12,"/>
 <result pre="subtypes. Absolute numbers of CD4+ and CD8+ T-cells decreased after" exact="alemtuzumab" post="persisting up to M24. Relative number of CD4+ lymphocytes"/>
 <result pre="increased again. Absolute numbers of NK-cells were not affected by" exact="alemtuzumab" post="treatment. Percentage of CD3-CD56+ NK-cells increased from baseline. There"/>
 <result pre="period, ceralifimod PK was assessed under fasting conditions and without" exact="itraconazole" post="coadministration: subjects received a single 0.15-mg dose of ceralifimod"/>
 <result pre="was assessed in combination with itraconazole: subjects received 200 mg" exact="itraconazole" post="once daily for 14 days starting on Day 23"/>
 <result pre="of ceralifimod 0.15 mg on Day 26 (fourth day of" exact="itraconazole" post="administration). Serial blood samples collected over 312 hours post"/>
 <result pre="and/or Pgp without dose adjustment. P978 CD19 mRNA quantification improves" exact="rituximab" post="treatment-to-target approach: a proof of concept study M Capobianco"/>
 <result pre="P979 Peripheral blood lymphocyte count: a possible immunological marker of" exact="fingolimod" post="efficacy? M Zaffaroni 1, D Baroncini 1, A Bianchi"/>
</results>
